ADDvise announces that the conditions for the early redemption of existing bonds 2021/2024 have been fulfilled

26 May 2023 - 15:38

ADDvise Group AB (publ) (the “Company”) announced on 12 May 2023 that it will redeem in full all of its outstanding bonds 2021/2024 with ISIN SE0015222088 (the “Bonds” and “Early Redemption”).

The Early Redemption was conditional upon the successful issuance of new bonds as announced by the Company through a press release on 11 May 2023 (the “New Bond Issue”). The issue date for the New Bond Issue occurred today and the conditions for the Early Redemption have therefore been fulfilled. The Early Redemption is therefore no longer conditional and will consequently occur on 9 June 2023. The redemption price together with accrued but unpaid interest up to (and including) 9 June 2023 will be paid to each person who is registered as owner of Bonds in the debt register maintained by Euroclear Sweden at the end of business on 1 June 2023.

More information regarding the Early Redemption can be found in the Company’s press release 12 May 2023.


For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
[email protected]


Hanna Myhrman, General Counsel
+46 709-82 92 23
[email protected]

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, [email protected], is the Company's Certified Adviser. Additional information is available at


Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
ADDvise Group AB
ADDvise Group develops and markets equipment and services to healthcare and research facilities....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More